Zhao Zheng, Zhang Kenan, Wang Zhiliang, Wang Kuanyu, Liu Xing, Wu Fan, Chen Jing
Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, P.R. China.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China.
Biomed Rep. 2019 Jan;10(1):3-9. doi: 10.3892/br.2018.1168. Epub 2018 Nov 14.
Gliomas are the most common and lethal type of primary malignant central nervous system tumors, with an extremely poor prognosis. The latest progression in the technological development of sequencing/microarray and bioinformatics has provided insights into the glioma genome. These technologies have generated large amounts of easily accessible biological omics data, providing an unprecedented opportunity to study glioma formation. According to the 2016 WHO organization classification of brain tumors, gliomas are currently diagnosed with respect to morphological and molecular tumor alterations, especially for isocitrate dehydrogenase and 1p/19q codeletions. In the present study, the comprehensive molecular profiling and available omics data resources for malignant gliomas were reviewed for novel insights into the biology and classification of these tumors. These molecular profiling resources may be useful for improving the understanding of malignant gliomas, and to accelerate the clinical, experimental and epidemiological studies that may lead to improvements in the lives of patients with glioma.
神经胶质瘤是原发性恶性中枢神经系统肿瘤中最常见且致命的类型,预后极差。测序/微阵列和生物信息学技术发展的最新进展为神经胶质瘤基因组提供了深入见解。这些技术产生了大量易于获取的生物组学数据,为研究神经胶质瘤的形成提供了前所未有的机会。根据2016年世界卫生组织(WHO)脑肿瘤组织学分类,目前神经胶质瘤的诊断依据形态学和分子肿瘤改变,尤其是异柠檬酸脱氢酶和1p/19q共缺失情况。在本研究中,对恶性神经胶质瘤的综合分子图谱和可用的组学数据资源进行了综述,以获得对这些肿瘤生物学特性和分类的新见解。这些分子图谱资源可能有助于增进对恶性神经胶质瘤的理解,并加速临床、实验和流行病学研究,从而改善神经胶质瘤患者的生活。